Polatuzumab vedotin + rituximab + lenalidomide in patients (pts) with relapsed/refractory (r/r) diffuse large b‐cell lymphoma (dlbcl): primary analysis of a phase 1b/2 trial
Hematological Oncology（2021）
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要